Key result
Percutaneous cardiopulmonary support for fulminant myocarditis resulted in a 75% acute survival rate, with survivors showing favorable long-term survival and cardiac function similar to non-PCPS patients.
Why the study?
Does percutaneous cardiopulmonary support affect long-term prognosis and cardiac function in patients with fulminant myocarditis?
Cohort (n=14)
Does percutaneous cardiopulmonary support affect long-term prognosis and cardiac function in patients with fulminant myocarditis?
Patients who survive the acute phase of fulminant myocarditis have a favorable long-term prognosis and recovery of cardiac function, regardless of whether percutaneous mechanical support was required for shock.
Supports favorable long-term outcomes in fulminant myocarditis survivors regardless of PCPS; leaves open whether support alters prognosis in randomized settings.
BACKGROUND: The long-term prognosis and cardiac function of fulminant myocarditis treated with percutaneous cardiopulmonary support (PCPS) was compared with the outcome of those not treated with PCPS. METHODS AND RESULTS: From 1991 to 2000, 14 patients with fulminant myocarditis (left ventricle ejection fraction (LVEF) < or =40%) were admitted to hospital. PCPS was necessary for treatment of shock in 8 (PCPS group), but not for the remaining 6 patients (non-PCPS group). In the PCPS group, 6 patients (75%) survived the critical phase and did not have any cardiac problems after discharge (range of follow-up period, 1.4-6.0 years). All patients in the non-PCPS group survived the acute phase; 1 patient had congestive heart failure 1.5 years after discharge, and another died from malignancy (follow-up period range, 2.2-9.4 years). Although the left ventricular ejection fraction (LVEF) of the PCPS group was significantly lower than that of the non-PCPS group in the acute phase, there was no significant difference in LVEF between the 2 groups in the chronic phase. CONCLUSION: Patients who survive the acute phase crisis of acute myocarditis have a favorable long-term survival rate, whether or not mechanical support is used.
No takes yet. Share an insight, caveat, or question.
Maejima et al. (2004) conducted a cohort in Fulminant myocarditis (n=14). Percutaneous cardiopulmonary support (PCPS) vs. No PCPS was evaluated on Survival of the critical/acute phase. Percutaneous cardiopulmonary support for fulminant myocarditis resulted in a 75% acute survival rate, with survivors showing favorable long-term survival and cardiac function similar to non-PCPS patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: